Carmustine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Carmustine
Carmustine: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Carmustine, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 15 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| hodgkin disease | licence in another country |
| non-hodgkin lymphoma | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| alk-positive large b-cell lymphoma |
| anaplastic astrocytoma |
| anaplastic ependymoma |
| anaplastic oligoastrocytoma |
| anaplastic oligodendroglioma |
| angiocentric glioma |
| astroblastoma |
| b-cell neoplasm |
| brain cancer |
| brain glioblastoma |
| chordoid glioma of the third ventricle |
| classic hodgkin lymphoma |
| classic hodgkin lymphoma, lymphocyte-rich type |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 8898H | Gliadel | Implants 7.7 mg, 8 | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating agent, nitrosourea class) |
| Myelosuppression Risk | High. Delayed and cumulative myelosuppression is expected with systemic or high-dose use |
| Emetogenicity Classification | High for intravenous use; the implant is local |
| Monitoring Items | FBC with differential, liver and renal function, and pulmonary function. Pulmonary toxicity was prominent in the retrieved high-dose studies |
| Handling Protection | Follow cytotoxic drug handling regulations |
This is a class-based summary. Please refer to the Product Information (PI) warnings and precautions for product-specific details.
Safety Considerations
No label-based warnings or contraindications were available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.
- Contraindication signals (knowledge graph, not label text): Associations include bone marrow and blood conditions (anaemia, leukopenia, thrombocytopenia, acute leukaemias), lung disease including pulmonary fibrosis, liver, kidney and gallbladder disease, infections (including fungal infection and meningitis), brain oedema, hydrocephalus, intracranial abscess and epilepsy.
- Drug interactions: 100 interactions were recorded. Of those shown, cimetidine is rated Major, naltrexone Moderate and levofloxacin Minor. Most others have an unspecified severity, including proton pump inhibitors, H2 blockers, corticosteroids, ondansetron, aprepitant, morphine and vancomycin.
- Literature signals: Pulmonary toxicity was common in high-dose regimens (39% in one series). Therapy-related acute leukaemia has also been reported after alkylator treatment of glioma.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.